Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on STOCK SPIRITS GROUP PLC. We currently have 10 research reports from 2 professional analysts.
|16Mar17 15:59||RNS||Director/PDMR Shareholding|
|15Mar17 16:40||RNS||Second Price Monitoring Extn|
|15Mar17 16:35||RNS||Price Monitoring Extension|
|08Mar17 07:00||RNS||Final Results|
|08Feb17 15:19||RNS||Holding(s) in Company|
|23Jan17 15:55||RNS||Death of a Director|
|11Jan17 07:00||RNS||Pre Close Trading Update|
Frequency of research reports
Research reports on
STOCK SPIRITS GROUP PLC
STOCK SPIRITS GROUP PLC
Undevilish detail implies more upside to come
09 Mar 17
While Stock Spirits (STCK LN, BUY, T/P 240p) appears in better shape than for some time, further improvements seem likely. Polish vodka market conditions remain competitive. But in our view attention to detail suggests the company is implementing the right brand strategy, appropriate pricing architecture and upgraded its sales function – hence, more upside to come. BUY
Positioned to perform
08 Mar 17
Stock Spirits (STCK LN, BUY, T/P 240p) preliminary 2016 results were in line with expectations, reconfirming their 11th January 2017 trading statement. Adjusted EBITDA was €51.5m compared with Bloomberg consensus and Whitman Howard estimates of €50.0m. The company are hosting an analyst presentation at 9.00am.
Strengthening the mix – 2016 trading update
11 Jan 17
Stock Spirits (STCK LN, BUY, T/P 240p) released a full year 2016 trading statement this morning. The company announced overall trading in the second half of 2016, and implicitly the full year, was in line with expectations. Whitman Howard’s own 2016 forecasts are for €264m revenue €50m EBITDA. The company is due to release preliminary results on 8 th March 2017.
20 Dec 16
Stock Spirits (STCK LN, BUY, T/P 240p) is due to release a full year 2016 trading statement on 11th January 2017. Ahead of then, we make modest adjustments to our 2016 numbers, which were slightly above consensus expectations (Source: Bloomberg). However, both Polish competitive conditions and Stock Sprits’ own earnings position appear significantly better than a year earlier. The company last warned on profits in a 27th November 2015 release.
Pricing foundations already laid
22 Nov 16
Stock Spirits (STCK LN, BUY, T/P 240p) competitor Roust’s recent shareholder/debtholder restructuring attracted interest from market commentators. There is a view that a change of ownership at Roust, and potential initial public offering may prompt a significant change in the Polish vodka market’s overall pricing dynamics.
Eyeing Up Opportunity
24 Mar 17
Produce Investment’s (PIL LN, BUY, T/P 210p) interim profits were well beneath inferred market expectations as delays in the recovery of ex-farm potato prices coincided with unusual costs associated with the company’s implementation of a new ERP system. Interim EBIT fell to £0.2m from £3.4m last year.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.